IMV EBITDA
Was ist das EBITDA von IMV?
EBITDA von IMV, Inc. ist -$43.81
Was ist die Definition von EBITDA?
Das EBITDA ist das Ergebnis eines Unternehmens vor Zinsen, Steuern, Abschreibungen und Amortisationen und ist eine Buchhaltungsgröße, die anhand des Nettoergebnisses eines Unternehmens berechnet wird, bevor Zinsaufwendungen, Steuern, Abschreibungen und Amortisationen abgezogen werden, um die derzeitige operative Ertragskraft eines Unternehmens zu ermitteln.
Although EBITDA is not a financial measure recognized in generally accepted accounting principles, it is widely used in many areas of finance when assessing the performance of a company, such as securities analysis. It is intended to allow a comparison of profitability between different companies, by discounting the effects of interest payments from different forms of financing (by ignoring interest payments), political jurisdictions (by ignoring tax), collections of assets (by ignoring depreciation of assets), and different takeover histories (by ignoring amortization often stemming from goodwill). EBITDA is a financial measurement of cash flow from operations that is widely used in mergers and acquisitions of small businesses and businesses in the middle market. It is not unusual for adjustments to be made to EBITDA to normalize the measurement allowing buyers to compare the performance of one business to another.
EBITDA von Unternehmen in Health Care Sektor auf TSX im Vergleich zu IMV
Was macht IMV?
IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Unternehmen mit ebitda ähnlich IMV
- Porch hat EBITDA von -$44.24
- Hybrid Kinetic hat EBITDA von -HKD$44.24
- Spruce Biosciences hat EBITDA von -$44.24
- Paratek Pharmaceuticals hat EBITDA von -$44.24
- Sino Prosper () hat EBITDA von -HKD$44.07
- Enthusiast Gaming hat EBITDA von -CAD$43.96
- IMV hat EBITDA von -$43.81
- ABIVAX Societe Anonyme hat EBITDA von -€43.78
- Abivax SA hat EBITDA von -€43.78
- mCloud Technologies hat EBITDA von -CAD$43.66
- China Parenting Network hat EBITDA von -¥43.63
- SKIL Infrastructure hat EBITDA von -₨43.55
- GMP Capital hat EBITDA von -CAD$43.53